deferoxamine has been researched along with Astrocytoma in 4 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Excerpt | Relevance | Reference |
---|---|---|
"Deferoxamine (DFO) caused decreased viability of human neuronal tumor cells (SK-N-MC neuroblastoma and U-373 MG astrocytoma) in a dose-dependent manner." | 3.69 | Deferoxamine-induced cytotoxicity in human neuronal cell lines: protection by free radical scavengers. ( Lee, YS; Wurster, RD, 1995) |
"Deferoxamine is an effective iron chelator and a potential therapeutic agent for use in minimizing free radical-mediated injury following trauma." | 1.30 | Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells. ( Connor, JR; Ye, Z, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Imaizumi, T | 1 |
Sakashita, N | 1 |
Mushiga, Y | 1 |
Yoshida, H | 1 |
Hayakari, R | 1 |
Xing, F | 1 |
Wang, L | 1 |
Matsumiya, T | 1 |
Tanji, K | 1 |
Chiba, Y | 1 |
Furudate, K | 1 |
Kawaguchi, S | 1 |
Murakami, M | 1 |
Tanaka, H | 1 |
Shimizu, T | 1 |
Uehara, T | 1 |
Nomura, Y | 1 |
Lee, YS | 1 |
Wurster, RD | 1 |
Ye, Z | 1 |
Connor, JR | 1 |
4 other studies available for deferoxamine and Astrocytoma
Article | Year |
---|---|
Desferrioxamine, an iron chelator, inhibits CXCL10 expression induced by polyinosinic-polycytidylic acid in U373MG human astrocytoma cells.
Topics: Astrocytoma; Cell Line, Tumor; Chemokine CXCL10; Deferoxamine; Dose-Response Relationship, Drug; Dru | 2015 |
Possible involvement of pyruvate kinase in acquisition of tolerance to hypoxic stress in glial cells.
Topics: Antimutagenic Agents; Apoptosis; Astrocytoma; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cel | 2004 |
Deferoxamine-induced cytotoxicity in human neuronal cell lines: protection by free radical scavengers.
Topics: Analysis of Variance; Antioxidants; Astrocytoma; Calcium Channel Blockers; Cell Survival; Deferoxami | 1995 |
Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells.
Topics: Astrocytoma; Brain Neoplasms; Chelating Agents; Deferoxamine; Gene Expression Regulation, Neoplastic | 1999 |